Esperion Therapeutics Inc (NASDAQ:ESPR) has been assigned an average rating of “Buy” from the fourteen research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $77.90.
Several analysts have commented on ESPR shares. Cowen set a $94.00 price target on shares of Esperion Therapeutics and gave the stock a “buy” rating in a research note on Sunday, May 5th. ValuEngine upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Northland Securities set a $65.00 price target on shares of Esperion Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Stifel Nicolaus reiterated a “buy” rating and issued a $112.00 price target on shares of Esperion Therapeutics in a research note on Friday, March 29th. Finally, BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th.
Esperion Therapeutics stock traded up $1.19 during mid-day trading on Friday, hitting $52.16. The stock had a trading volume of 248,729 shares, compared to its average volume of 722,768. The company has a market capitalization of $1.32 billion, a P/E ratio of -6.92 and a beta of 2.11. Esperion Therapeutics has a one year low of $35.80 and a one year high of $60.99.
Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share for the quarter, topping the consensus estimate of $0.64 by $2.43. The firm had revenue of $145.42 million during the quarter, compared to the consensus estimate of $69.35 million. During the same period in the prior year, the company posted ($1.73) EPS. As a group, analysts anticipate that Esperion Therapeutics will post -2.09 earnings per share for the current fiscal year.
In other Esperion Therapeutics news, CEO Timothy M. Mayleben bought 5,000 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were purchased at an average cost of $48.73 per share, for a total transaction of $243,650.00. Following the transaction, the chief executive officer now owns 51,163 shares of the company’s stock, valued at $2,493,172.99. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Nicole Vitullo sold 15,329 shares of the company’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $44.73, for a total transaction of $685,666.17. Following the sale, the director now owns 8,319 shares in the company, valued at $372,108.87. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 65,000 shares of company stock worth $3,155,550 and have sold 48,329 shares worth $2,280,206. 7.70% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in ESPR. Advisor Group Inc. raised its position in shares of Esperion Therapeutics by 44.4% during the 4th quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 291 shares in the last quarter. Parallel Advisors LLC bought a new position in Esperion Therapeutics during the 1st quarter valued at about $80,000. Rehmann Capital Advisory Group bought a new position in Esperion Therapeutics during the 4th quarter valued at about $97,000. Marshall Wace North America L.P. bought a new position in Esperion Therapeutics during the 1st quarter valued at about $164,000. Finally, Marshall Wace LLP bought a new position in Esperion Therapeutics during the 1st quarter valued at about $186,000.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.